Lobaplatin(CAS: 135558-11-1)

Lobaplatin (CAS: 135558-11-1) is regulated under the Globally Harmonized System (GHS) for classification and labeling of chemicals, and falls under the European Union's Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) regulation. Additionally, the U.S. Food and Drug Administration (FDA) and Environmental Protection Agency (EPA) have specific requirements for the handling and disposal of pharmaceutical compounds in the U.S.

There are several alternatives to Lobaplatin (CAS: 135558-11-1) that can be used in synthesis, including other platinum-based antitumor agents such as cisplatin and carboplatin. These alternatives may vary in efficacy, toxicity, and synthesis complexity, but can serve as viable substitutes in specific chemical reactions.

The market for Lobaplatin (CAS: 135558-11-1) is growing due to its effectiveness in treating certain types of cancer. Research trends are focusing on its mechanism of action, potential side effects, and the development of more targeted therapies. Additionally, there is increasing interest in the optimization of its synthesis and delivery methods for improved therapeutic outcomes.

Waste containing Lobaplatin (CAS: 135558-11-1) should be collected in appropriate containers and handled under proper personal protective equipment. The waste should then be disposed of using professional hazardous waste disposal services. Environmental protection measures include minimizing exposure, proper labeling, and following local regulations on hazardous waste management.